The present invention is direct to an co-fruit pulp based edible composition in which an agricultural fruit byproduct base material, in conjunction with a hydrocolloid, is treated with pressure and/or heat to form an edible composition that is dimensionally stable, ambient stable for at least 9 months, has a moisture content greater than 50 wt. %, has a pH less than 4.5, has a water activity greater than 0.5, is commercially sterile, is free of artificial flavors and/or artificial colors, has a solids content greater than 10 wt. %, and does not exhibit syneresis or exhibits syneresis. Alternatively, the base material contains an edible fruit and/or vegetable and/or nut byproduct alone or in combination with the co-fruit pulp. Also provided is a method for preparation of the edible composition.

The present invention addresses the problem of providing a novel heat stress relieving agent that can be taken easily, conveniently and safely even by infants and the elderly, who are susceptible to heat stress such as heat illness, that rapidly promotes sweating in a heat stress environment, and that prevents, alleviates, or improves symptoms and disorders caused by heat stress, such as heat illness. The above problem is solved by providing a heat stress relieving agent containing glycosyl hesperetin as an effective ingredient, and a basal body temperature maintaining agent containing glycosyl hesperetin as an effective ingredient.

A composition and method of increasing ketotic efficiency and improving flavor of a combination of a (D)-β-hydroxybutyric acid and (D)-1,3 butanediol composition for increasing circulating ketone levels is disclosed. Exemplary compositions may be incorporated into food, supplement, and beverage products.

A gummy includes an inner portion, a formulation having a dispersion including an active ingredient contained in the inner portion; and an outer portion which surrounds the inner portion. The active ingredient includes one or more nutrients such as cannabinoids and dietary supplement. The dispersion includes one or more of a liposome emulsion; a nanoemulsion, and a microemulsion, each containing the active ingredient. A method of making such gummy having the cannabinoids and/or dietary supplement formulation in the inner portion thereof includes setting up a central filling apparatus having a shell syrup hopper, a central filling hopper, and a manifold branch and nozzle mechanism; filling the shell syrup hopper with the base material; filling the central filling hopper with the formulation; dispensing the base material and the formulation in the manifold branch and nozzle mechanism, and further into the gummy mold; and extracting the gummy from the gummy mold.

In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNFα composition, or a composition capable of down-modulating TNFα activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.

A food contains a vitamin D.sub.2 mushroom oil. A content of vitamin D.sub.2 in unit dose of the food is not less than 0.5 μg. The vitamin D.sub.2 mushroom oil has a peroxide value less than or equal to 15 meq/kg and an acid value less than or equal to 3 mg/g. The vitamin D.sub.2 mushroom oil is prepared through a step of subjecting a vitamin D.sub.2-containing mushroom powder to extraction with an edible oil. The food contains a nutrient selected from the group consisting of perilla oil, walnut oil, linseed oil, peanut oil, olive oil, arachidonic acid (ARA), docosahexaenoic acid (DHA), vitamin A, calcium alginate and a combination thereof.

A low glycemic gummy composition is provided. The gummy composition includes a gelling component in a sufficient amount to provide a cohesive gelled product, and a low glycemic index sugar component having a glycemic index of not more than 20. The gummy composition includes not less than 50% weight of the low glycemic index sugar component. In some embodiments, the gummy composition further includes an active component, wherein the active component comprises a vitamin composition, a mineral composition, an amino acid composition, an antioxidant composition, an herbal composition, or an active pharmaceutical ingredient (API) composition. The gummy composition may be substantially free of D-glucose, D-fructose, and sugar substitutes such as non-sugar sweeteners and sugar alcohols.

Disclosed herein is a nutritional supplement containing apple cider vinegar (ACV), including compositions, formulations, and combinations of ingredients in the ACV nutritional supplement, as well as processes for manufacturing these supplements. The disclosed nutritional supplement can include ACV, a gelling agent such as pectin or gelatin, an oligosaccharide, a disaccharide, and water.

Provided is an oral composition, including the following components (A), (B), and (C): (A) non-polymer catechins; (B) rutin; and (C) astragalin, wherein a content of the component (A) in solids is from 2 mass % to 50 mass %, wherein a mass ratio between the component (A) and the component (B), [(B)/(A)], is from 0.05×10.sup.−2 to 50×10.sup.−2, and wherein a mass ratio between the component (A) and the component (C), [(C)/(A)], is from 1.0×10.sup.−3 to 50×10.sup.−3.

A gummy includes an inner portion, a formulation having a dispersion including a plurality of liposomal vesicles contained in the inner portion; and an outer portion which surrounds the inner portion. The formulation includes an active ingredient including cannabidiol (CBD), phospholipid contained in the liposomal vesicles, and a optionally added coating material, the CBD being incorporated within the liposomal vesicles. A method of making such gummy having the CBD formulation in the inner portion thereof includes setting up a central filling apparatus having a shell syrup hopper, a central filling hopper, and a manifold branch and nozzle mechanism; filling the shell syrup hopper with the base material; filling the central filling hopper with the CBD formulation; dispensing the base material and CBD formulation in the manifold branch and nozzle mechanism, and further into the gummy mold; and extracting the gummy from the gummy mold.